Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

California Budget Could Force Seniors To Nursing Homes, Drive Up Costs
NPR reports that California"s $26.3 billion budget deficit is marginalizing seniors who rely on California state-provided health care and service to help them manage their lives.
generic viagra online
Clinton Says U.S. Will Work With India To Address Health Challenges, Hunger
The U.S. will work to address the health challenges facing India among other countries and will aim to improve maternal and child health care services through comprehensive dialogue, Secretary of State Hillary Clinton said on Friday after visiting a Self Employed Women"s Association (SEWA) trade outlet in Mumbai, India, PTI/Yahoo! News reports. Clinton said, "Our government is already spending a lot of money on HIV/AIDS but we wanted to add maternal and child health to that commitment as it is important for India." She added that the funding will be used to combat tuberculosis and polio, "which are also problems in India" (7/18).
News of the day
Children Now Enjoy More Freedom At Home, But Are More Restricted Outside The Home
Children have certainly mastered the art of selecting, negotiating and even refusing the chores their parents assign to them. This growth in personal autonomy at home over the last few decades could be the result of shrinking opportunities to participate in activities outside the home, without Mom and Dad looking over their shoulder, according to Dr. Markella Rutherford from Wellesley College in the US. Her analysis1 of back issues of the popular US magazine, Parents, maps how the portrayal of parental authority and children"s autonomy has changed over the last century. Her findings are published online in Springer"s journal Qualitative Sociology.
Diagnostics

Orexo Announces Positive Phase III Results For KW-2246 In Japan

Orexo"s (STO:ORX) partner in Japan, Kyowa Hakko Kirin, has obtained positive phase III results in Japan for KW-2246, which is approved for the treatment of breakthrough pain in cancer patients and marketed under the brand AbstralTM in Europe. Kyowa Hakko Kirin will now proceed with preparations for a new-drug application for KW-2246 in Japan for use in continuous pain management of acute cancer pain (breakthrough pain). Orexo announces that Kyowa Hakko Kirin, Orexo"s partner in Japan, today confirms that it has obtained positive clinical phase III results for KW-2246 in Japan. The clinical study results revealed a statistically significant difference between KW-2246 and the placebo, and clinical effectiveness was confirmed. In addition, with regard to safety, no unacceptable side effects were found during the clinical study period. Kyowa Hakko Kirin will now proceed with the preparations for a new-drug application for KW-2246 in Japan. According to the market research institute Datamonitor, the Japanese market for opioids is one of the largest markets in the world (Datamonitor 2008, Commercial and Pipeline Insight: Opioids). Torbjç¶rn Bjerke, President and CEO of Orexo, comments: "The positive phase III results in Japan are an important milestone for our successful collaboration with Kyowa Hakko Kirin. This marks another important step in the international development of AbstralTM and strengthening Orexo in the process of becoming a profitable pharmaceutical company". Trial design The clinical study was conducted using a crossover design involving a double-blind placebo-controlled trial, targeting patients to whom an opioid analgesic was administered at fixed intervals for intermediate to severe cancer pain and who use a morphine preparation for breakthrough pain, and a non-blind controlled trial with a morphine preparation. About Abstral Abstral is a fast-dissolving tablet for sub-lingual administration of fentanyl, intended for the management of breakthrough cancer pain in patients who are already receiving opioid analgesics. It is based on Orexo"s unique and patented sublingual tablet technology in which a rapidly dissolving tablet is placed under the tongue and the active substance is absorbed by the mucous membrane. Currently Abstral is sold in Sweden, UK and Germany and is ready for launch in France. In Sweden, Abstral is sold through Orexo"s and ProStrakan"s joint venture, ProStrakan AB. The product is being prepared for registration in Japan and in the US the clinical phase III is finalized. License agreements have been signed with Kyowa Hakko Kirin for Japan and with ProStrakan for EU and the US. Distribution agreements regarding Abstral for Russia and the CIS, Bulgaria and Rumania have been signed with Gedeon Richter. A distribution agreement has been signed with Hospira for the Southeast Asian market. For the Chinese market, Orexo has signed a distribution agreement with NovaMed, and for the Israeli market Orexo has signed a distribution agreement with Neopharm. About Kyowa Hakko Kirin Kyowa Hakko Kirin Co., Ltd. is engaged in the manufacturing and marketing of medical products and pharmaceuticals. As the parent company of the Kyowa Hakko Kirin Group, it manages the business activities in the Bio-Chemicals and Chemicals segments with the Pharmaceuticals segment as its core business. More information can be found at http://www.kyowa-kirin.co.jp/english/index.html. Orexo


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009